Sources:
Stege CAM, Nasserinejad K, Levin M-D, et al. Geriatric impairments and low muscle mass are associated with treatment discontinuation and overall survival in newly diagnosed non-transplant eligible multiple myeloma patients (nte-NDMM) treated with dose-adjusted melphalan-prednisone-bortezomib (MPV) – results of the Dutch HOVON 123 study. ASH Annual Meeting and Exposition 2018, abstract 1889.
Stege CAM, Nasserinejad K, Levin M-D, et al. Geriatric impairments and low muscle mass are associated with treatment discontinuation and overall survival in newly diagnosed non-transplant eligible multiple myeloma patients (nte-NDMM) treated with dose-adjusted melphalan-prednisone-bortezomib (MPV) – results of the Dutch HOVON 123 study. ASH Annual Meeting and Exposition 2018, abstract 1889.